Molecular Targeting Probes - Radioactive & Nonradioactive -> Preclinical Probes for Oncology 1000

1000 - Targeting of PD-L1 in mouse xenograft tumors by 89Zr-atezolizumab is specific but strongly mass-dependent (ID 52)

Session Name
Preclinical Probes for Oncology Posters
Speakers
Authors
Presentation Topic
Molecular Targeting Probes - Radioactive & Nonradioactive -> Preclinical Probes for Oncology
Presentation Number
1000

Previous Eposter
643 - Image-based biomarkers for bone sarcomas using F-18 FDG PET/CT: determination of optimal parameters and their prognostic threshold (ID 625)

Next Eposters
1001 - Immuno-PET imaging of 89Zr labeled novel anti-ED-B domain antibody (ID 53)
1002 - Deglycosylated CD8-specific immunoPET probe prevents antibody-mediated depletion of CD8+ immune cells (ID 54)
1003 - Evaluation of binding specificity of target-specific radioligands in xenografts by multi-modal PET and MR imaging using the Hen’s egg test chorioallantoic membrane (HET-CAM) model (ID 55)
1006 - Immuno-PET Imaging of the VEGFR-2 Expression in Prostate Cancer Using 89Zr-labeled Ramucirumab (ID 58)
1008 - The case for DOTA as a pharmacokinetic modulator for 18F-labeled peptides: DOTA-[18F]AMBF3-LLP2A for improved PET imaging of VLA-4 over-expression in murine melanoma (ID 60)
1009 - A new PET imaging agent for monitoring HER2 status using Trastuzumab antibody conjugated with a novel 89 Zr-chelator. (ID 61)
1010 - ImmunoPET imaging with radiolabeled CAEL-101 for personalizing amyloidosis immunotherapy (ID 62)
1014 - Fluorinated Small Molecule Inhibitors of Fibroblast Activation Protein-α for Imaging of Tumor Stroma (ID 66)
1019 - In Vivo Characterization of PD-L1 Expression in Breast Cancer by Immuno-PET with 89Zr-labeled Avelumab (ID 71)
1020 - Iodine 131-labbled AuNPs-TAT nanoparticlesTargetCellsNucleiin ColonCancerfor Enhanced Radioisotope Therapy (ID 72)